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INVOLVEMENT OF NUCLEAR FACTOR KB IN 
THE REGULATION OF CYCLOOXYGENASE-2 EXPRESSION BY 
INTERLEUKIN-1 IN RHEUMATOID SYNOVIOCYTES 
LESLIE J. CROFFORD, BING TAN, CONOR J. McCARTHY, and TIMOTHY HLA 
Objective. To evaluate involvement of the tran- 
scription factor nuclear factor KB (NF-KB) in the in- 
creased expression of cyclooxygenase-2 (COX-2) stimu- 
lated by interleukin-lp (IL-1p) in primary rheumatoid 
synoviocytes. 
Methods. We treated early-passage rheumatoid 
synoviocytes with IL-lp and examined the time course 
of NF-KB translocation to the nucleus by Western blot 
analysis, as well as NF-KB binding to the COX-2 
promoter/enhancer by electrophoretic mobility shift as- 
say. We correlated the time course of NF-KB binding 
with expression of COX-2 messenger RNA (mRNA) and 
protein. Synoviocytes were then treated with either 
sense or antisense phosphorothioate-modified oligo- 
nucleotides derived from the transcription start site of 
the human NF-KB p65 RNA. We analyzed NF-KB bind- 
ing to the COX-2 promoter and COX-2 protein levels 
after these treatments. 
Results. IL-1p rapidly stimulated the transloca- 
tion of the p65, p50, and c-re1 NF-KB subunits from the 
cytoplasm to the nucleus. Electrophoretic mobility shift 
assay demonstrated binding to 2 NF-KB sites within the 
COX-2 promoter/enhancer, with a time course identical 
to that of nuclear localization of NF-KB. Supershift 
analysis revealed that binding activity was due primar- 
ily to the p65-p50 heterodimer and the p50 homodimer. 
With appropriate lag time after NF-KB binding, COX-2 
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mRNA and protein were increased. Pretreatment of RA 
synoviocytes with NF-KB p65 antisense oligonucleotides 
resulted in decreased binding to the COX-2 promoter 
and decreased COX-2 protein expression. 
Conclusion. These data demonstrate that signal- 
ing via the NF-KB pathway is involved in regulation of 
COX-2 expression induced by IL-1p in RA synoviocytes. 
Rheumatoid arthritis (RA) is a chronic inflam- 
matory disease characterized by proliferative and inva- 
sive synovitis. Rheumatoid synovial tissues release large 
quantities of prostaglandins (PGs), mainly PGE,, 
PGF,,, prostacyclin, and thromboxane, that are impor- 
tant mediators of inflammation (1-4). PGE, may also 
play a key role as a mediator of erosion of cartilage and 
juxtaarticular bone, and induction of angiogenesis (5-7). 
PG synthesis is initiated by release of arachidonic 
acid from cell membranes (8,9). Arachidonate is con- 
verted to PGH, by cyclooxygenase (COX; prostaglandin 
H synthase), the central enzyme in the PG synthetic 
pathway (10). COX-1 is the constitutively expressed 
isoform of COX. In contrast, COX-2 is expressed only at 
low levels under basal conditions, but is markedly in- 
duced by proinflammatory or mitogenic stimuli and 
suppressed by glucocorticoids (11-17). High levels of 
immunoreactive COX are present in RA synovia as 
compared with synovia from patients with osteoarthritis 
or from normal subjects (18). The COX-2 isoform is 
detectable by specific immunohistochemical analysis in 
vivo in human RA synovial tissues (16). Primary ex- 
planted rheumatoid synovial tissues express both COX-1 
and COX-2. After treatment with the proinflammatory 
cytokine interleukin-1P (IL-lp), expression of COX-2, 
but not COX-1, messenger RNA (mRNA) and peptide 
is markedly increased. Dexamethasone eliminates 
COX-2, but not COX-1, expression in unstimulated 
explants. Dexamethasone also dramatically inhibits IL- 
l-induced increases in COX-2 expression. COX-2 reg- 
ulation by IL-10 and dexamethasone in cultured 
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rheumatoid synovial fibroblast-like cells (synoviocytes) 
parallels the findings in primary explants (16). 
The  proinflammatory cytokine IL-1 is present in 
high levels in synovial fluid and peripheral blood of 
patients with RA (19), and systemic levels of IL-1p 
correlate with disease activity (20). The  majority of 
IL-1p present in inflamed rheumatoid synovia is pro- 
duced by macrophages; however, synoviocytes also syn- 
thesize IL-1 (21). Finally, injection of IL-1 into rabbit 
knee joints produces inflammatory synovitis (22,23). 
IL-1 exerts its effects by binding to the type I IL-1 
receptor (IL-1RI) (24,25). The  IL-1RI signaling pathway 
is incompletely understood (26,27). Nevertheless, it is 
clear that IL-1-induced activation of the transcription 
factor nuclear factor KB (NF-KB) is a major signaling 
pathway for IL-1-induced gene expression (27). 
NF-KB activity is mediated by a family of tran- 
scription factor subunits that bind D N A  as hetero- or 
homodimers. The  subunits are present in the cytoplasm 
in inactive form, bound to inhibitory proteins such as 
M A D ~ / I K B ~ .  A variety of extracellular stimuli, includ- 
ing IL-1, induce degradation of IKB. Dissociation of 
NF-KB from cytoplasmic inhibitors is followed by trans- 
location of the complex to the nucleus, then binding to 
specific DNA sequences (28). NF-KB-responsive ele- 
ments are required for the transcriptional regulation of 
a number of mediators of immune and inflammatory 
processes (29). 
The  promoter region of the human COX-2 gene 
contains 2 motifs with sequence similarity to  the consen- 
sus binding site for NF-KB (30). Since the I L - ~ ~ I N F - K B  
pathway is of significance in the  coordinate regulation of 
inflammatory processes and this transcriptional pathway 
has not been examined for COX-2, we investigated the 
role of NF-KB in the regulation of the human COX-2 
gene in RA synoviocytes. 
MATERIALS AND METHODS 
Synoviocyte culture. Synovial tissues were obtained 
from patients with RA, at the time of total joint replacement 
surgery. Tissues were minced, and treated for 4 hours with 4 
mgiml collagenase (type I; Worthington Biochemical, Free- 
hold, NJ) in Dulbecco's modified Eagle's medium (DMEM) at 
37°C in 5% CO,. Dissociated cells were plated in DMEM 
supplemented with 10% human AB serum (BioWhittaker, 
Walkersville, MD), 10% fetal bovine serum (Gibco, Grand 
Island, NY), penicillin (100 unitdml), and streptomycin (100 
Fgirnl). Cells were used between the third and tenth passages. 
Where indicated, cells were treated with human recombinant 
IL-lP (1 ngiml; Genzyme, Cambridge, MA). 
Preparation of cytoplasmic and nuclear extracts. Ex- 
tracts were prepared using a protocol modified from the 
method described by Schreiber et al (31). Cells were 
trypsinized, pelleted, washed in ice-cold phosphate buffered 
saline, and resuspended in 5 volumes of ice-cold low-salt 
cytoplasmic buffer (10 mM HEPES, pH 7.9 at 4"C, 10 mM KC1, 
0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol [DTT], 
and protease inhibitors). Cells were allowed to swell on ice for 
15 minutes, after which Triton X-100 was added to a final 
concentration of 0.25% and cells were vortexed vigorously to 
disrupt plasma membranes. Intact nuclei were pelleted by 
centrifugation, and the cytoplasmic extract was aliquoted and 
immediately frozen. Nuclei were resuspended in high-salt 
buffer (20 mM HEPES, pH 7.9, 400 mM NaCI, 1 mM EDTA, 
1 mM EGTA, 1 mM DTT, and protease inhibitors) and placed 
on a shaking platform for 15 minutes at 4°C to disrupt the 
nuclear membrane. The nuclear extract was collected after 
centrifugation at 13,500g for 5 minutes at 4"C, aliquoted, and 
immediately frozen. All extracts were stored at -80°C until 
used. 
Western blot analysis. Fifty micrograms of protein 
from cytoplasmic or nuclear extracts was separated by electro- 
phoresis in a denaturing sodium dodecyl sulfate (SDS)- 
polyacrylamide gel and transferred to an activated nylon 
membrane (PVDF-Plus; Micron Separations, Westborough, 
MA). Rabbit polyclonal antibodies to the amino terminus of 
p65 and p105 and the carboxy terminus of c-re1 were a 
generous gift from Dr. Nancy Rice (National Cancer Institute, 
Frederick, MD). Rabbit polyclonal IgG to a synthetic human 
COX-2 polypeptide, and a COX-2 electrophoresis standard, 
were purchased from Caymen Chemical Co. (Ann Arbor, MI). 
Membranes were blocked in 5% (weightivolume) Carnation 
nonfat dry milk in Tris buffered saline (TBS; 150 mM NaCI, 20 
mM Tris HCl, pH 7.6), primary antibodies were added in fresh 
blocking solution as indicated and incubated for 1 hour at 
room temperature, and membranes were washed 3 times in 
TBS containing 0.1% Tween 20. Membranes were then incu- 
bated for 1 hour at room temperature with horseradish 
peroxidase-conjugated anti-rabbit immunoglobulin diluted 
1:5,000 in TBS containing 1% bovine serum albumin, then 
washed as above. The ECL (enhanced chemiluminescence) 
system (Amersham, Arlington Heights, IL) was used for 
detection. 
Electrophoretic mobility shift assay. Complementary 
oligonucleotides with sequences derived from the human 
COX-2 promoter region with homology to consensus NF-KB 
binding sites were synthesized. The oligonucleotide from -455 
to -427 contained the potential NF-KB site located at -446 to 
CCCG-3'), and the oligonucleotide from -231 to -202 con- 
tained the potential NF-KB site located at -221 to -212 
(5'-CAGGAGAGTGGGACTACCCCCTCTGCTCC-3'). An 
oligonucleotide containing a well-characterized NF-KB con- 
sensus site from the human HLA-A3 gene ( 5 ' -  
CCTTGGGGATTCCCCAACTCC-3') (32) and an oligo- 
nucleotide containing a consensus SP-1 binding site (5'- 
ATTCGATCGGGGCGGGGCGAGC-3') were used in 
competition experiments. The underlined sequences delineate 
consensus binding sites within the synthetic oligonucleotides. 
Complementary strands were synthesized with 5' overhanging 
ends, annealed, and double-stranded oligonucleotides were 
labeled with '*P-dCTP using the Klenow fragment of DNA 
polymerase (Boehringer Mannheim, Indianapolis, IN). Nu- 
-437 (5'-CGGCGGGAGAGGGGATTCCCTGCGCC 
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Figure 1. Western blot analysis of nuclear factor KB (NF-KB) subunits in cytoplasmic and nuclear extracts after 
stimulation of rheumatoid synoviocytes with interleukin-lp (IL-1p; 1 nglml). Synoviocytes were used between the 
third and tenth passages. Cells were treated for the indicated number of minutes (min), after which cytoplasmic 
and nuclear extracts were prepared as described in Materials and Methods. Proteins (50 pg) were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blotting was then performed using 
antisera to NF-KB family members as indicated. The experiment was performed 3 times with similar findings; a 
representative result is shown. 
clear extracts (5 pg protein) were incubated with 2 pg poly(d1- 
dC) (Pharmacia, Piscataway, NJ) for 5 minutes in a buffer 
containing 100 mM HEPES, 100 mM KCl, 13 mM MgCl,, 1 
mM EDTA, 2.5 mM DTT, 1% glycerol, and 2% Ficoll 400. 
Radiolabeled probe (20,000 counts per minute) was added 
with or without unlabeled competitor as indicated, and the 
binding reaction was allowed to proceed for 15 minutes on ice 
and 15 minutes at room temperature. Reaction mixtures were 
loaded directly on nondenaturing 4% polyacrylamide gels 
containing 0.0225M Tris-borate and 0.5 mM EDTA, and 
electrophoresed with buffer recirculation for 90 minutes. Gels 
were dried under vacuum followed by autoradiography. “Su- 
pershift” assays were performed as above, except that nuclear 
extracts were incubated together with antibodies to p65, ~ 1 0 5 1  
50, or c-re1 (described above) for 1 hour prior to addition of the 
probe. 
Reverse transcription-polymerase chain reaction. To- 
tal RNA was prepared using Tri-Reagent (Molecular Research 
Center, Cincinnati, OH). Complementary DNA (cDNA) was 
prepared by reverse transcription of 5 pg total RNA in 50 pl 
containing 50 mM Tris HCI (pH 8.3), 40 mM KCl, 6 mM 
MgCI,, 1 mM DTT, 0.4 mM dNTPs, 2 p M  random hexamer 
primers (Perkin-Elmer Cetus, Nonvalk, CT), 0.2 units/pl 
RNase inhibitor (Perkin-Elmer Cetus), and 8 units/pI M-MLV 
reverse transcriptase (Life Technologies, Bethesda, MD). Re- 
action mixtures were incubated at room temperature for 10 
minutes, at 42°C for 30 minutes, and at 95°C for 5 minutes. 
Complementary DNA was diluted 10-fold, and used for each 
PCR amplification. PCRs were performed in 50 pl containing 
5 pl cDNA, 10 mM Tris HCl (pH 8.3), 50 mM KC1, 2 mM 
MgCl,, 50 pl4 dNTPs, [ ( u - ~ ~ P I ~ C T P  (3,000 Ci/mmole; Amer- 
sham), and 0.025 pl Tuq polymerase (Perkin-Elmer Cetus). 
The oligonucleotide primers used were as follows: for COX-2, 
sense 5’-TTCAAATGAGATTGTGGGAAAATTGCT-3’, 
antisense 5‘-AGATCATCTCTGCCTGAGTATCIIT-3‘; for 
G3PDH, sense 5’-CCACCCATGGCAAATTCCATGGCA- 
3’, antisense 5‘-TCTAGACGGCAGGTCAGGTCCACC-3’. 
Cycling conditions were as follows: denaturing at 95°C for 1 
minute, annealing at 65°C for 1 minute, and extension at 72°C 
for 1 minute (25 cycles for G3PDH and 35 cycles for COX-2). 
Northern blot analysis. RNA was prepared as de- 
scribed above. Twenty micrograms of total RNA was subjected 
to electrophoresis through a 1.5% agarose/4% formaldehyde 
gel, and transferred to a nylon membrane (Nytran; Schleicher 
& Schuell, Keene, NH). A probe was generated using a 1.8-kb 
fragment of the human COX-2 coding sequence by the random 
prime method (Prime-It RmT; Stratagene, La Jolla, CA), or 
from a cDNA fragment of human G3PDH generated by PCR 
using primers as described above. Membranes were hybridized 
in 50% formamide at 42°C for 24 hours with 2-5 X lo6 cpm/ml 
cDNA probe. Washing was performed twice for 15 minutes in 
2X saline-sodium citrate (SSC), 0.1% SDS at room tempera- 
ture, and twice for 15 minutes in 0.1X SSC, 0.1% SDS at 65°C. 
The membranes were exposed to Kodak XAR film for up to 2 
weeks at -80°C with intensifying screens. Densitometry was 
performed using a scanner from Molecular Dynamics (Sunny- 
vale, CA). COX-2 expression was normalized to G3PDH 
detected on the same Northern blot, for quantitation. 
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Figure 2. Electrophoretic mobility shift assays demonstrating binding to cis sequences of the human cyclooxygenase-2 (Cox-2) promoterienhancer 
with homology to nuclear factor KB (NFKB) binding sites after stimulation of rheumatoid synoviocytes with interleukin-lp (IL-1p; 1 ng/ml). A, A 
30-basepair end-labeled double-stranded oligonucleotide centered on the -446 to -437 NFKB site was used as the probe. B, The 30-bp probe 
contains the NFKB sequence from -221 to -212. Asterisks indicate bands that were not significantly affected by treatment of the cells with IL-lp, 
and were not NFKB. NS = nonspecific complex; Free = free double-stranded oligonucleotide probe; min = minutes. The experiments were 
performed 3 times; representative results are shown. 
Antisense oligonucleotides. Phosphorothioate- 
modified sense and antisense oligonucleotides corresponding 
to the 5’ end of the mRNA for the human p65 subunit of 
NF-KB and extending 3 nucleotides upstream of the initiation 
codon were synthesized (Applied Biosystems, Foster City, 
CA). The antisense oligonucleotide was previously shown by 
Sokoloski and colleagues to exert biologic effects (33). Se- 
quences were as follows: p65 sense, 5‘-GCCATGGACGAA- 
CCTGTTCCCC-3’; p65 antisense 5’-GGGGAACAGTTC- 
GGTCCATGGC-3’ (33). 
RESULTS 
Findings of Western blot analysis of NF-KB. 
Western blotting of rheumatoid synoviocyte cytoplasmic 
and nuclear extracts (Figure 1) revealed that at baseline, 
rheumatoid synoviocytes contained p65, p105/50, and 
c-re1 in the cytoplasm. Constitutive nuclear localization 
of these NF-KB subunits was variable, but much lower 
than cytoplasmic levels, if detectable at all. After treat- 
ment with IL-10 (1 ndml), translocation of p65, p105/50, 
and c-rel from the cytoplasm to the nuclear compart- 
ment occurred within 15 minutes, was maximal by 30 
minutes, and began to decline by 1 hour after treatment. 
By 4 hours after treatment with IL-lp, the levels of these 
NF-KB family members in the nucleus and cytoplasm 
had returned to near baseline levels. 
Findings of electrophoretic mobility shift assays. 
The time course of binding to the potential NF-KB sites 
derived from the human COX-2 promoter is shown in 
Figures 2A and B. Using the probe containing either the 
-446 to -437 or the -221 to -212 sequences, we 
demonstrated increased binding within 15 minutes after 
treatment with IL-1p; this reached maximal levels by 30 
minutes to 1 hour, then began to decline by 2-4 hours. It 
should be noted that there were 2 additional bands not 
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Figure 3. Electrophoretic mobility shift competition assays demonstrating specificity of binding to the NFKB sites of the Cox-2 promoter/enhancer. 
A, The probe contained the -446 to -437 NFKB site from human Cox-2, and unlabeled competitor is as indicated. The HLA-A3-derived 
competitor was a 21-basepair sequence containing a consensus NFKB binding site, and the SP-1 competitor contained the binding site for that 
transcription factor which is unrelated to NFKB. B, The probe contained the -221 to -212 NFKB binding site. Cold competitor was as indicated. 
Asterisks indicate bands that were not decreased by the Cox -446 to -437 or HLA-A3 NFKB binding sites. See Figure 2 for definitions. 
significantly regulated by IL-1p that were present when 
the probe containing the -221 to -212 sequence was 
used. The identity of the proteins in these complexes, 
and their significance, is not known. 
Competition electrophoretic mobility shift exper- 
iments using the probe containing the -446 to -437 
NF-KB site (Figure 3A) revealed 2 complexes that were 
specifically competed away by unlabeled oligonucleo- 
tides containing the -447 to -436 COX-2 NF-KB site, 
the -221 to -212 COX-2 NF-KB site, and the HLA-A3 
NF-KB site. The double-stranded oligonucleotide con- 
taining the consensus SP-1 binding site did not compete 
significantly with the labeled probe. Competition exper- 
iments using the labeled probe containing the -221 to 
-212 COX-2 NF-KB site (Figure 3B) demonstrated 2 
complexes that were competed away by all unlabeled 
double-stranded oligonucleotides containing NF-KB 
sites. Two additional complexes that were not signifi- 
cantly diminished by NF-KB oligonucleotides were seen. 
These are the same complexes that were not significantly 
affected by treatment with IL-1p. 
We used “supershift assays,” in which extracts 
were preincubated with antibodies to the p65, p105/50, 
and c-rel NF-KB family members prior to electrophoretic 
mobility shift assays, to evaluate the composition of the 
complexes binding to the COX-2 NF-KB sites (Figures 
4A and B). We determined that the upper complex, 
detected using labeled probes containing either of the 
COX-2 NF-KB binding sites, contained a p65-p50 hetero- 
dimer. The lower complex seen in Figure 4A comprised 
a p50 homodimer. A barely detectable “supershift” 
complex was present after preincubation with the anti- 
c-re1 antibody, leaving open the possibility that a c-rel- 
containing heterodimer migrating with the same prop- 
erties of the other complex(es) also binds to the human 
COX-2 promoter NF-KB sites. 
Time course of IL-lestimulated COX-2 expres- 
sion. The time course for induction of endogenous 
COX-2 mRNA by IL-1/3 (1 ng/ml) was investigated using 
RT-PCR and Northern blotting. Compared with levels 
of the housekeeping gene, G3PDH, there was a rapid 
rise of endogenous COX-2 message by 30 minutes after 
stimulation, which peaked at 1 hour and began to 
diminish by 2 hours. A second rise in COX-2 mRNA 
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Figure 4. Electrophoretic mobility shift competition “supershift” assays identifying NFKB family members that bind to the Cox-2 promoter. A, 
Using the probe containing the -446 to -437 sequence, the ~ 6 5 5 ~ 5 0  heterodimer was identified as forming the upper complex, since preincubation 
with antisera to both these subunits yielded a supershift (asterisk) and a decrease in the intensity of the upper band. The lower band was formed 
by binding of a p50 homodimer, as indicated by loss of the lower complex using antisera to the p50 subunit alone. A faint band was detected with 
the higher concentration of antisera to c-rel, possibly indicating that a complex containing c-re1 may bind to this site. B, Using the probe containing 
the -221 to -212 NFKB site, binding of a p65-pSO heterodimer was demonstrated. Several non-NFKB bands are present (see Figures 2B and 3B). 
See Figure 2 for definitions. 
expression was seen at 4 hours (Figures SA and B). The 
RT-PCR was performed 4 times with similar results. 
Northern blotting confirmed the RT-PCR result. 
COX-2 protein levels had increased by 1 hour, 
and expression continued to be increased at 24 hours 
after treatment (Figure 6). 
Response to treatment with NF-KB p65 antisense 
oligonucleotide. To determine the functional effect of 
NF-KB binding on induction of COX-2 mRNA, we 
pretreated RA synoviocytes with phosphorothioate- 
modified antisense oligonucleotides corresponding to 
the 5‘ end of the p6.5 mRNA and including 3 nucleotides 
upstream of the initiation codon (40 pA4) or sense 
oligonucleotides (40 pA4) as negative controls. Binding 
of the p6.5-p.50 heterodimer to the COX-2 promoter was 
markedly diminished in the antisense-treated synovio- 
cytes by 4 hours after IL-1p treatment (Figure 7). We 
further demonstrated that the p6.5 antisense phosphoro- 
thioate oligonucleotides diminished expression of IL- 
1P-stimulated COX-2 polypeptide at 4 hours after treat- 
ment (Figure 8). There are 2 probable reasons that 
COX-2 polypeptide expression was not decreased to the 
same extent as NF-KB binding at the 4-hour time point. 
First, use of antisense technology prevents only synthesis 
of new p6.5, not translocation of preformed cytoplasmic 
p6.5. Therefore, no change in early NF-KB binding to the 
COX-2 promoter after treatment with the p65 antisense 
oligonucleotides would be expected. Transcription could 
be increased through NF-KB-dependent mechanisms 
prior to new synthesis of p65, leading to some increase of 
COX-2 polypeptide expression. Second, as outlined be- 
low, there are multiple transcription factors that may 
stimulate transcription of COX-2. 
DISCUSSION 
PGs mediate both inflammatory and destructive 
features of RA. The classic signs of acute inflammation 
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Figure 5.  Time course of increased Cox-2 messenger RNA (mRNA) expression in rheumatoid 
synoviocytes after stimulation with IL-lp (1 ngiml), in studies using A, reverse transcriptase- 
polymerase chain reaction (RT-PCR) and B, Northern blot analysis. Increased Cox-2 expression is 
shown with G3PDH mRNA expression from the same RT samples or by reprobing the same filter 
(shown for comparison). No bands were present when PCR was performed with no RT or no RNA 
in the RT reactions. See Figure 2 for other definitions. 
(pain, swelling, erythema, and warmth), can be repro- 
duced by PG actions which stimulate vasodilatation, 
increase vascular permeability, and contribute to noci- 
ceptor sensitization (34). PGE, contributes to increased 
expression of matrix metalloproteinases that are impor- 
tant mediators of tissue degradation (3,5,6,35). In addi- 
tion, PGE, stimulates production of vascular endothelial 
growth factor by synoviocytes that may contribute to 
angiogenesis (7). It is likely that increased local PG 
production during inflammation is stimulated by inter- 
actions between resident cells and infiltrating mono- 
nuclear cells. These mononuclear cells probably contrib- 
ute to increased PG production by mechanisms 
including direct cell-cell contact and, in particular, 
elaboration of cytokines (16,35). Regulation of PG 
production in RA involves multiple enzymatic steps, and 
may differ depending on cell type. For example, IL-1 
increases secretory group I1 phospholipase A, (sPLA,), 
but not cytosolic PLA, (cPLA,), in chondrocytes (35), 
while stimulating cPLA,,but not sPLA,, in synoviocytes 
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Figure 6. Western blot demonstrating the time course of increased Cox-2 polypeptide expression in rheumatoid 
synoviocytes after stimulation with IL-lp (1 ngiml). Cox-2 expression was not detectable at baseline, but was 
increased by 2 hours ("). Expression continued to increase over the 24-hour time period. The typical doublet 
represents differently glycosylated forms of Cox-2 and migrates at -72 kd. Migration of protein standards is 
indicated on the left. ' = minutes; see Figure 2 for other definitions. 
(17). In all cell types within joint tissues that have been 
examined, COX-2 expression is dramatically increased 
by IL-1 (16,17,37-39). Regulation of COX-2 expression 
is likely a critical step in determining levels of PG 
produced in the joint during inflammation (40). 
We demonstrated that IL-1p increases transloca- 
tion of NF-KB subunits to the nucleus in rheumatoid 
synoviocytes. The cells used in these experiments were 
predominantly type B synoviocytes, based on our previ- 
ous experience that synovial cells prepared in this way 
express only very low levels of CD11WCD18 (M01) and 
CD14 (M02) (41). Fujisawa and colleagues recently 
demonstrated that tumor necrosis factor a (TNFa) also 
increases activation of NF-KB in rheumatoid synovial 
cells (42). We have also shown that TNFa stimulates 
translocation of NF-KB to the nucleus (data not shown). 
p65 Sense p65 Antisense 
1 ~ - 1 6 ( 1  ng /d )  0 15' 3 0  1' 2' 4' 0 15' 3 0  1' 2" 4' 
Figure 7. Electrophoretic mobility shift assay demonstrating loss of the p65ip50 band 4 hours (") after treatment 
with antisense oligonucleotide to p65 (40 lul.i). The probe used contained the -446 to-437 NFKB site. There was 
no effect on binding when the p65 sense oligonucleotide was used. ' = minutes; see Figure 2 for other definitions. 
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Figure 8. Western blot demonstrating decreased Cox-2 expression after stimulation with IL-lP (1 ngiml) in 
synoviocytes pretreated with antisense oligonucleotide to p65 (40 pM). The typical doublet represents differently 
glycosylated forms of Cox-2 and migrates at -72 kd. Migration of protein standards is indicated on the left. ‘ = 
minutes; O = hours; see Figure 2 for other definitions. 
In addition, TNFa increases NF-KB binding to the 
COX-2 promoter, COX-2 mRNA expression, and 
polypeptide expression (data not shown). These data 
suggest that both IL-1p and TNFa may use the NF-KB 
pathway to stimulate COX-2 expression in rheumatoid 
synoviocytes. 
Constitutive nuclear NF-KB subunit expression in 
the established primary rheumatoid synoviocyte cell 
lines used in our experiment?? was variable, but usually 
quite low. However, it is of interest that Okamoto and 
colleagues reported that freshly isolated rheumatoid 
synovial cells constitutively express nuclear NF-KB (43), 
and Marok and coworkers demonstrated expression of 
an active form of NF-KB in vivo in RA synovia (44). The 
latter investigators used antisera specific for the nuclear 
localization sequences of the Rel-A (p65) subunit of 
NF-KB, unmasked only after dissociation from IKB and 
therefore presumed to represent “active” subunit, to 
perform immunohistochemical analysis of RA synovia. 
They demonstrated constitutive nuclear expression of 
Rel-A (p65), predominantly localized to the blood ves- 
sels in patients with an acute disease flare at the time of 
tissue sampling, but also in the synovial lining containing 
predominantly type A synoviocytes and subsynovia 
where type B synoviocytes are localized (44). These 
findings may be explained, at least in part, by persistent 
COX-2 expression in vivo in patients with RA, since 
immunohistochemical staining with specific anti-COX-2 
antisera was also localized predominantly to the blood 
vessel endothelial cells (16). 
In parallel with IL-1-stimulated nuclear translo- 
cation of NF-KB, we demonstrated induction of specific 
NF-KB binding to 2 cis sequences in the human COX-2 
promoter. IL-lpstimulated increases in COX-2 mRNA 
and polypeptide expression occurred after an appropri- 
ate lag time after NF-KB binding. Inhibition of NF-KB 
binding by pretreatment with phosphorothioate-modified 
p65 antisense oligonucleotides led to diminished COX-2 
protein expression. These data demonstrate that inhibi- 
tion of a transcription factor can directly affect expres- 
sion of endogenous COX-2. 
Investigation of NF-KB regulation of COX-2 
transcription is of interest in light of recent data suggest- 
ing that one mechanism by which glucocorticoids exert 
down-regulatory effects may be by inhibition of NF-KB 
translocation to the nucleus. Although glucocorticoids, 
through interaction with the glucocorticoid receptor 
(GR), can function by binding directly to the glucocor- 
ticoid response element (GRE) in promoter regions to 
mediate effects on gene transcription, there are no 
GREs in most immune response genes, including 
COX-2 (30). In addition, although glucocorticoids also 
act to inhibit transcription via physical association be- 
tween the GR and activating protein-1 (AP-l), no AP-1 
site has been identified as yet in the human COX-2 
promoter. It was, however, recently reported that glu- 
cocorticoids enhance expression of IKB, which results in 
decreased nuclear localization and binding of NF-KB 
(45,46). This may occur either through “recapture” of 
NF-KB in the cytoplasm prior to nuclear translocation, 
or translocation of newly synthesized IKB to the nucleus, 
where it can promote dissociation of DNA-bound 
NF-KB (45,46). 
While NF-KB is one mechanism by which IL-1 
may stimulate COX-2 expression, biologic effects of IL-1 
are complex and relatively poorly understood. Many of 
the cellular responses to binding of the IL-1 ligand to 
IL-1RI take place very rapidly (within 15 minutes), 
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including translocation of transcription factors to the 
nucleus, as we demonstrated. After ligand binding, the 
complex is rapidly internalized, with some complexes 
degraded and others found associated with the nucleus. 
However, it has been demonstrated that late displace- 
ment of IL-1 from the type I receptor blocks transcrip- 
tion, suggesting that the continued presence of IL-1 on 
the IL-1RI is critical to amplification of IL-1-mediated 
biologic effects (26). While most intracellular effects of 
IL-1 occur rapidly and are short-lived, at least one 
potential mediator of IL-1 activity with sustained activity 
was described by Guesdon and coworkers, who demon- 
strated the persistent presence of active p-casein kinase 
(47). Transcriptional results mediated by this pathway 
have not yet been fully defined. 
Multiple transcription factors, including not only 
NF-KB, but also nuclear factor for IL-6 (NF-IL6, also 
known as the CCATT enhancer binding protein or 
cjEBPS) and the c-fos and c-jun components of AP-1, 
are activated in response to IL-1 in various cell systems 
(26). Binding sites for NF-IL6 (cjEBP8) are present in 
the COX-2 promoter. Using constructs containing the 
human COX-2 promoter linked to a luciferase reporter 
gene, Inoue and coworkers demonstrated that c/EBPG 
was involved in transcriptional regulation of human 
COX-2 in bovine and human endothelial cells, and that 
binding of this transcription factor to both the NF-IL6 
and CRE binding sites probably occurred (48). Using 
similar methodology, that group also reported a func- 
tional requirement for the CRE element of the human 
COX-2 promoterjenhancer for COX-2 expression dur- 
ing differentiation of U937 monocytic cells (49). 
IL-1 may also mediate posttranscriptional regu- 
lation of COX-2 expression. COX-2 transcripts exhibit a 
very high turnover rate, likely mediated by multiple 
AU-rich sequences located in the 3'-untranslated region 
of the mRNA (37). These sequences are present in a 
number of lymphokine and protooncogene mRNAs, and 
accelerate mRNA degradation (50). Ristimaki and col- 
leagues demonstrated that the half-life of COX-2 
mRNA in an immortalized human umbilical vein endo- 
thelial cell line was approximately 1 hour. Treatment 
with IL-1 increased the stability of the COX-2 transcript, 
an effect that was enhanced by a transcription inhibitor 
(37). These data support the possibility of a short-lived 
factor(s) inhibited by IL-1 that degrades COX-2 mRNA. 
Our data and data from other groups support the 
concept of multiple mechanisms underlying the effects 
of IL-1 on COX-2 expression. We demonstrated that 
NF-KB is involved in IL-1-stimulated COX-2 mRNA 
expression. NF-IL6 (c/EBPG) involvement in transcrip- 
tional regulation of COX-2 remains to be evaluated in 
synoviocytes, but clearly plays a role in expression of the 
human COX-2 gene in other cell types (48). Increased 
mRNA stability mediated by IL-1 may be another 
mechanism likely to be important in increased COX-2 
expression (37). Finally, the contribution of glucocorti- 
coid effects on NF-KB nuclear translocation to inhibition 
of COX-2 expression and PG production must be eval- 
uated. Understanding the molecular mechanisms under- 
lying increased and sustained COX-2 protein expression 
and PG production in rheumatoid synovial tissues may 
help to elucidate factors responsible for chronic inflam- 
mation and tissue destruction in RA. 
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